GSK plc (NYSE: GSK) Stock Competitors & Peer Comparison
See GSK's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GSK and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $51.95 | -0.43% | 106.1B | 11.44 | $4.63 | +3.39% |
| LLY | $1,217.74 | +2.16% | 1.1T | 37.64 | $31.49 | +0.55% |
| JNJ | $260.21 | +1.26% | 624.7B | 24.16 | $10.73 | +2.04% |
| ABBV | $245.21 | +0.55% | 434.4B | 24.13 | $10.19 | +2.79% |
| MRK | $130.53 | +1.68% | 317.5B | 40.05 | $3.21 | +2.61% |
| NVS | $156.19 | +1.28% | 297.2B | 17.99 | $8.69 | +3.03% |
| AZN | $161.66 | +1.03% | 250.3B | 17.43 | $9.26 | +1.30% |
| AMGN | $413.74 | +2.20% | 221.8B | 18.37 | $22.37 | +2.39% |
| NVO | $47.17 | +2.61% | 209.8B | 11.75 | $4.02 | +3.82% |
| GILD | $133.29 | +1.86% | 165.4B | -341.56 | -$0.39 | +2.42% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
GSK vs LLY Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while LLY trades at $1,217.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas LLY's P/E ratio is 37.64. In terms of profitability, GSK's ROE is +0.24%, compared to LLY's ROE of +0.93%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
GSK vs JNJ Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, JNJ has a market cap of 624.7B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while JNJ trades at $260.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas JNJ's P/E ratio is 24.16. In terms of profitability, GSK's ROE is +0.24%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GSK is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
GSK vs ABBV Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, ABBV has a market cap of 434.4B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while ABBV trades at $245.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas ABBV's P/E ratio is 24.13. In terms of profitability, GSK's ROE is +0.24%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, GSK is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
GSK vs MRK Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, MRK has a market cap of 317.5B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while MRK trades at $130.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas MRK's P/E ratio is 40.05. In terms of profitability, GSK's ROE is +0.24%, compared to MRK's ROE of +0.18%. Regarding short-term risk, GSK is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
Novartis AG (NYSE: NVS)
GSK vs NVS Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, NVS has a market cap of 297.2B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while NVS trades at $156.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas NVS's P/E ratio is 17.99. In terms of profitability, GSK's ROE is +0.24%, compared to NVS's ROE of +0.30%. Regarding short-term risk, GSK is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
GSK vs AZN Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, AZN has a market cap of 250.3B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while AZN trades at $161.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas AZN's P/E ratio is 17.43. In terms of profitability, GSK's ROE is +0.24%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GSK is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
GSK vs AMGN Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while AMGN trades at $413.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas AMGN's P/E ratio is 18.37. In terms of profitability, GSK's ROE is +0.24%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
GSK vs NVO Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, NVO has a market cap of 209.8B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while NVO trades at $47.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas NVO's P/E ratio is 11.75. In terms of profitability, GSK's ROE is +0.24%, compared to NVO's ROE of +0.59%. Regarding short-term risk, GSK is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for GSK.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
GSK vs GILD Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, GILD has a market cap of 165.4B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while GILD trades at $133.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas GILD's P/E ratio is -341.56. In terms of profitability, GSK's ROE is +0.24%, compared to GILD's ROE of -0.16%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
GSK vs PFE Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, PFE has a market cap of 152.4B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while PFE trades at $26.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas PFE's P/E ratio is 8.77. In terms of profitability, GSK's ROE is +0.24%, compared to PFE's ROE of +0.05%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
GSK vs BMY Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, BMY has a market cap of 132.2B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while BMY trades at $65.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas BMY's P/E ratio is 10.91. In terms of profitability, GSK's ROE is +0.24%, compared to BMY's ROE of +0.47%. Regarding short-term risk, GSK is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
Sanofi (NASDAQ: SNY)
GSK vs SNY Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while SNY trades at $43.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas SNY's P/E ratio is 9.47. In terms of profitability, GSK's ROE is +0.24%, compared to SNY's ROE of +0.06%. Regarding short-term risk, GSK is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
GSK vs BIIB Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, BIIB has a market cap of 30.7B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while BIIB trades at $207.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas BIIB's P/E ratio is 13.13. In terms of profitability, GSK's ROE is +0.24%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
GSK vs ZTS Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, ZTS has a market cap of 30.5B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while ZTS trades at $73.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas ZTS's P/E ratio is 11.04. In terms of profitability, GSK's ROE is +0.24%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, GSK is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for GSK.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
GSK vs HZNP Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.24%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
GSK vs GRFS Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, GRFS has a market cap of 6.7B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while GRFS trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas GRFS's P/E ratio is 9.12. In terms of profitability, GSK's ROE is +0.24%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
GSK vs OGN Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while OGN trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas OGN's P/E ratio is 4.06. In terms of profitability, GSK's ROE is +0.24%, compared to OGN's ROE of +0.23%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
GSK vs CELG-RI Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.24%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, GSK is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for GSK.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
GSK vs CTOR Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, CTOR has a market cap of 72.5M. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas CTOR's P/E ratio is -1.66. In terms of profitability, GSK's ROE is +0.24%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, GSK is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for GSK.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
GSK vs SCLX Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, SCLX has a market cap of 59M. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while SCLX trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas SCLX's P/E ratio is -0.18. In terms of profitability, GSK's ROE is +0.24%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
GSK vs SCLXW Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, GSK's ROE is +0.24%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
GSK vs MIRA Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, MIRA has a market cap of 31.1M. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while MIRA trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas MIRA's P/E ratio is -0.51. In terms of profitability, GSK's ROE is +0.24%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
GSK vs BDSIW Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GSK's ROE is +0.24%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
GSK vs CRXT Comparison August 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 106.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $51.95 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.44, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.24%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here